Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares Sold by Polar Asset Management Partners Inc.

Polar Asset Management Partners Inc. reduced its stake in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 20.0% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 394,400 shares of the biopharmaceutical company's stock after selling 98,500 shares during the quarter. Polar Asset Management Partners Inc. owned 0.25% of Ocular Therapeutix worth $3,368,000 as of its most recent filing with the SEC.

Several other hedge funds have also modified their holdings of OCUL. Barclays PLC raised its holdings in shares of Ocular Therapeutix by 37.1% during the 3rd quarter. Barclays PLC now owns 511,522 shares of the biopharmaceutical company's stock valued at $4,451,000 after buying an additional 138,441 shares during the period. SG Americas Securities LLC raised its holdings in shares of Ocular Therapeutix by 58.7% during the 4th quarter. SG Americas Securities LLC now owns 71,698 shares of the biopharmaceutical company's stock valued at $612,000 after buying an additional 26,511 shares during the period. China Universal Asset Management Co. Ltd. raised its holdings in shares of Ocular Therapeutix by 11.2% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 33,336 shares of the biopharmaceutical company's stock valued at $285,000 after buying an additional 3,347 shares during the period. Deltec Asset Management LLC raised its holdings in shares of Ocular Therapeutix by 0.6% during the 4th quarter. Deltec Asset Management LLC now owns 2,616,373 shares of the biopharmaceutical company's stock valued at $22,344,000 after buying an additional 16,300 shares during the period. Finally, Rhumbline Advisers raised its holdings in shares of Ocular Therapeutix by 2.7% during the 4th quarter. Rhumbline Advisers now owns 213,601 shares of the biopharmaceutical company's stock valued at $1,824,000 after buying an additional 5,682 shares during the period. 59.21% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Ocular Therapeutix

In related news, insider Pravin Dugel sold 21,219 shares of the business's stock in a transaction that occurred on Friday, May 23rd. The stock was sold at an average price of $7.18, for a total transaction of $152,352.42. Following the completion of the transaction, the insider now owns 3,499,099 shares in the company, valued at $25,123,530.82. The trade was a 0.60% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Richard L. Md Lindstrom acquired 10,000 shares of Ocular Therapeutix stock in a transaction that occurred on Thursday, May 8th. The shares were bought at an average price of $6.96 per share, with a total value of $69,600.00. Following the transaction, the director now directly owns 172,704 shares in the company, valued at approximately $1,202,019.84. This trade represents a 6.15% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last quarter, insiders sold 29,079 shares of company stock worth $208,739. 2.30% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the company. HC Wainwright reiterated a "buy" rating and set a $15.00 target price on shares of Ocular Therapeutix in a report on Thursday. JMP Securities set a $19.00 price objective on Ocular Therapeutix in a research note on Tuesday, March 4th. William Blair assumed coverage on Ocular Therapeutix in a report on Tuesday, April 8th. They set an "outperform" rating on the stock. Needham & Company LLC dropped their price objective on Ocular Therapeutix from $15.00 to $14.00 and set a "buy" rating on the stock in a report on Tuesday, May 6th. Finally, Royal Bank of Canada assumed coverage on Ocular Therapeutix in a report on Tuesday, March 18th. They set an "outperform" rating and a $17.00 price objective on the stock. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $16.25.

Ocular Therapeutix Stock Down 1.6%

OCUL stock traded down $0.13 during midday trading on Friday, hitting $8.01. 2,177,691 shares of the company's stock were exchanged, compared to its average volume of 1,411,133. The stock has a market capitalization of $1.28 billion, a price-to-earnings ratio of -6.07 and a beta of 1.51. The firm has a 50 day moving average price of $7.37 and a 200-day moving average price of $7.93. The company has a current ratio of 13.01, a quick ratio of 12.94 and a debt-to-equity ratio of 0.19. Ocular Therapeutix, Inc. has a 12-month low of $4.79 and a 12-month high of $11.78.

Ocular Therapeutix (NASDAQ:OCUL - Get Free Report) last issued its earnings results on Monday, March 3rd. The biopharmaceutical company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.05). The firm had revenue of $17.08 million during the quarter, compared to analyst estimates of $16.89 million. Ocular Therapeutix had a negative return on equity of 45.18% and a negative net margin of 283.74%. On average, analysts anticipate that Ocular Therapeutix, Inc. will post -0.98 EPS for the current year.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.